Insider Buying Boosts Psychedelic‑Therapeutics Firm’s Growth Outlook and FDA Momentum
Insider buying by the chief medical officer of a psychedelic‑therapeutics company signals strong confidence and market potential, backed by promising Phase 2a data and an accelerating FDA review timeline.
5 minutes to read